Regular physical activity is associated with lower cancer incidence and mortality, as well as
with a lower rate of tumour recurrence. The epidemiological evidence is supported by …

The remarkable success of cancer immunotherapies has provided new hope to cancer
patients. Unfortunately, a significant proportion of patients remain unable to respond to …

A range of emerging therapeutic approaches for the treatment of cancer aim to induce or
augment endogenous T cell responses. Chimeric antigen receptor (CAR) T cell therapy …

Chimeric antigen receptor (CAR) T cell expansion and persistence emerged as key efficacy
determinants in cancer patients. These features are typical of early-memory T cells, which …

Chimeric antigen receptor (CAR) T-cell therapy is an individualized immunotherapy that
genetically reprograms a patient's T cells to target and eliminate cancer cells …

CAR-T (chimeric antigens receptor-T) cell therapy is a breakthrough therapy of the twenty-
first century for the management of different malignancies including lymphomas and …

Background aims The most widely accepted starting materials for chimeric antigen receptor
T-cell manufacture are autologous CD3+ T cells obtained via the process of leukapheresis …

Lymphocytes such as T‐cells can be genetically transduced to express a synthetic chimeric
antigen receptor (CAR) that re‐directs their cytotoxic activity against a tumour‐expressed …

Chimeric antigen receptor T-cell (CAR T) therapy is a new and rapidly developing field.
Centers across the world are gaining more experience using these innovative anti-cancer …

Whether as a cure or bridge to transplant, chimeric antigen receptor (CAR)-T cell therapies
have shown dramatic outcomes for the treatment of hematologic malignancies, and …